Subcutaneous Injection of Autologous Adipose Tissue-derived Stromal Vascular Fraction Into the Fingers of Patients With Systemic Sclerosis : Controlled Clinical Trial With Efficacy Assessment
Phase of Trial: Phase II
Latest Information Update: 14 Jun 2017
At a glance
- Drugs ECCS 50 (Primary)
- Indications Systemic scleroderma
- Focus Therapeutic Use
- Acronyms SCLERADEC II
- 14 Jun 2017 According to a Cytori Therapeutics media release, updates from the study will be presented at the Annual European Congress of Rheumatology (EULAR 2017).
- 10 Jan 2017 According to a Cytori Therapeutics media release, completion of enrollment in this trail is anticipated in mid-2017 with data unblinding and analysis estimated to occur by the end of 2017.
- 30 May 2016 According to the information on the company website, the results from this and the US STAR trial (700271953) will be used to obtain EU conditional marketing authorisation and normal marketing authorisation.